Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099
The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal c...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 1998-04, Vol.16 (4), p.1310-1317 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1317 |
|---|---|
| container_issue | 4 |
| container_start_page | 1310 |
| container_title | Journal of clinical oncology |
| container_volume | 16 |
| creator | M Al-Sarraf M LeBlanc P G Giri K K Fu J Cooper T Vuong A A Forastiere G Adams W A Sakr D E Schuller J F Ensley |
| description | The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers.
Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology.
Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P < .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P < .001).
We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival. |
| doi_str_mv | 10.1200/JCO.1998.16.4.1310 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79805079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79805079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-6e71fa2867eae72f3b47b806da4a35fbba7dff7e0c67e40783cded0628fd2d963</originalsourceid><addsrcrecordid>eNpVkE-L1TAUxYMo43P0CwhCFuKuNX_aJnUnj1ErA7NRcBfS5OY1Q9vUpJ3hufObm8c8ZnB14dxzzk1-CL2lpKSMkI_f9zclbVtZ0qasSsopeYZ2tGaiEKKun6MdEZwVVPJfL9GrlG4JoZXk9QW6aOuaEU536O9-gClEbX1YB4h6OeI7iGlL-D_Nz3jRq4d5TfjerwPW9k7PBiyedQrLoONxPoAesTmp8RPOUgLcdV3umW2Y_J_s7eYV4iGGbcFp3ewRE9K2r9ELp8cEb87zEv38cvVj_624vvna7T9fF6YiYi0aENRpJhsBGgRzvK9EL0ljdaV57fpeC-ucAGKyIyckNxYsaZh0ltm24Zfow0PvEsPvDdKqJp8MjKOeIWxJiVaSmog2G9mD0cSQUgSnluin_ENFiTpxV5m7OnFXtFGVOnHPoXfn9q2fwD5GzqDz_v15r5PRo8tUjE-PNsYoZY18euTgD8O9j6DSpMcxlzJ1a8LTvX9B4ptA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79805079</pqid></control><display><type>article</type><title>Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Journals@Ovid Complete</source><creator>M Al-Sarraf ; M LeBlanc ; P G Giri ; K K Fu ; J Cooper ; T Vuong ; A A Forastiere ; G Adams ; W A Sakr ; D E Schuller ; J F Ensley</creator><creatorcontrib>M Al-Sarraf ; M LeBlanc ; P G Giri ; K K Fu ; J Cooper ; T Vuong ; A A Forastiere ; G Adams ; W A Sakr ; D E Schuller ; J F Ensley</creatorcontrib><description>The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers.
Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology.
Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P < .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P < .001).
We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.1998.16.4.1310</identifier><identifier>PMID: 9552031</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - radiotherapy ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Combined Modality Therapy ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Humans ; Male ; Medical sciences ; Middle Aged ; Nasopharyngeal Neoplasms - drug therapy ; Nasopharyngeal Neoplasms - mortality ; Nasopharyngeal Neoplasms - radiotherapy ; Neoplasm Recurrence, Local ; Pharmacology. Drug treatments ; Radiation-Sensitizing Agents - administration & dosage ; Radiation-Sensitizing Agents - adverse effects ; Survival Analysis</subject><ispartof>Journal of clinical oncology, 1998-04, Vol.16 (4), p.1310-1317</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-6e71fa2867eae72f3b47b806da4a35fbba7dff7e0c67e40783cded0628fd2d963</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3716,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2211268$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9552031$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>M Al-Sarraf</creatorcontrib><creatorcontrib>M LeBlanc</creatorcontrib><creatorcontrib>P G Giri</creatorcontrib><creatorcontrib>K K Fu</creatorcontrib><creatorcontrib>J Cooper</creatorcontrib><creatorcontrib>T Vuong</creatorcontrib><creatorcontrib>A A Forastiere</creatorcontrib><creatorcontrib>G Adams</creatorcontrib><creatorcontrib>W A Sakr</creatorcontrib><creatorcontrib>D E Schuller</creatorcontrib><creatorcontrib>J F Ensley</creatorcontrib><title>Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers.
Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology.
Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P < .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P < .001).
We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Combined Modality Therapy</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nasopharyngeal Neoplasms - drug therapy</subject><subject>Nasopharyngeal Neoplasms - mortality</subject><subject>Nasopharyngeal Neoplasms - radiotherapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Pharmacology. Drug treatments</subject><subject>Radiation-Sensitizing Agents - administration & dosage</subject><subject>Radiation-Sensitizing Agents - adverse effects</subject><subject>Survival Analysis</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE-L1TAUxYMo43P0CwhCFuKuNX_aJnUnj1ErA7NRcBfS5OY1Q9vUpJ3hufObm8c8ZnB14dxzzk1-CL2lpKSMkI_f9zclbVtZ0qasSsopeYZ2tGaiEKKun6MdEZwVVPJfL9GrlG4JoZXk9QW6aOuaEU536O9-gClEbX1YB4h6OeI7iGlL-D_Nz3jRq4d5TfjerwPW9k7PBiyedQrLoONxPoAesTmp8RPOUgLcdV3umW2Y_J_s7eYV4iGGbcFp3ewRE9K2r9ELp8cEb87zEv38cvVj_624vvna7T9fF6YiYi0aENRpJhsBGgRzvK9EL0ljdaV57fpeC-ucAGKyIyckNxYsaZh0ltm24Zfow0PvEsPvDdKqJp8MjKOeIWxJiVaSmog2G9mD0cSQUgSnluin_ENFiTpxV5m7OnFXtFGVOnHPoXfn9q2fwD5GzqDz_v15r5PRo8tUjE-PNsYoZY18euTgD8O9j6DSpMcxlzJ1a8LTvX9B4ptA</recordid><startdate>19980401</startdate><enddate>19980401</enddate><creator>M Al-Sarraf</creator><creator>M LeBlanc</creator><creator>P G Giri</creator><creator>K K Fu</creator><creator>J Cooper</creator><creator>T Vuong</creator><creator>A A Forastiere</creator><creator>G Adams</creator><creator>W A Sakr</creator><creator>D E Schuller</creator><creator>J F Ensley</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980401</creationdate><title>Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099</title><author>M Al-Sarraf ; M LeBlanc ; P G Giri ; K K Fu ; J Cooper ; T Vuong ; A A Forastiere ; G Adams ; W A Sakr ; D E Schuller ; J F Ensley</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-6e71fa2867eae72f3b47b806da4a35fbba7dff7e0c67e40783cded0628fd2d963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Combined Modality Therapy</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nasopharyngeal Neoplasms - drug therapy</topic><topic>Nasopharyngeal Neoplasms - mortality</topic><topic>Nasopharyngeal Neoplasms - radiotherapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Pharmacology. Drug treatments</topic><topic>Radiation-Sensitizing Agents - administration & dosage</topic><topic>Radiation-Sensitizing Agents - adverse effects</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>M Al-Sarraf</creatorcontrib><creatorcontrib>M LeBlanc</creatorcontrib><creatorcontrib>P G Giri</creatorcontrib><creatorcontrib>K K Fu</creatorcontrib><creatorcontrib>J Cooper</creatorcontrib><creatorcontrib>T Vuong</creatorcontrib><creatorcontrib>A A Forastiere</creatorcontrib><creatorcontrib>G Adams</creatorcontrib><creatorcontrib>W A Sakr</creatorcontrib><creatorcontrib>D E Schuller</creatorcontrib><creatorcontrib>J F Ensley</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>M Al-Sarraf</au><au>M LeBlanc</au><au>P G Giri</au><au>K K Fu</au><au>J Cooper</au><au>T Vuong</au><au>A A Forastiere</au><au>G Adams</au><au>W A Sakr</au><au>D E Schuller</au><au>J F Ensley</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>1998-04-01</date><risdate>1998</risdate><volume>16</volume><issue>4</issue><spage>1310</spage><epage>1317</epage><pages>1310-1317</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers.
Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology.
Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P < .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P < .001).
We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>9552031</pmid><doi>10.1200/JCO.1998.16.4.1310</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 1998-04, Vol.16 (4), p.1310-1317 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79805079 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Journals@Ovid Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - radiotherapy Cisplatin - administration & dosage Cisplatin - adverse effects Combined Modality Therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Male Medical sciences Middle Aged Nasopharyngeal Neoplasms - drug therapy Nasopharyngeal Neoplasms - mortality Nasopharyngeal Neoplasms - radiotherapy Neoplasm Recurrence, Local Pharmacology. Drug treatments Radiation-Sensitizing Agents - administration & dosage Radiation-Sensitizing Agents - adverse effects Survival Analysis |
| title | Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A13%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemoradiotherapy%20versus%20radiotherapy%20in%20patients%20with%20advanced%20nasopharyngeal%20cancer:%20phase%20III%20randomized%20Intergroup%20study%200099&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=M%20Al-Sarraf&rft.date=1998-04-01&rft.volume=16&rft.issue=4&rft.spage=1310&rft.epage=1317&rft.pages=1310-1317&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.1998.16.4.1310&rft_dat=%3Cproquest_cross%3E79805079%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79805079&rft_id=info:pmid/9552031&rfr_iscdi=true |